CN Patent

CN104284662A — 晶体及包含该晶体的药物制剂

Assigned to Pola Pharma Inc · Expires 2015-01-14 · 11y expired

What this patent protects

本发明的目的是提供提高卢立康唑的溶解度的方法。本发明公开了由卢立康唑和具有1至4个碳原子的短链醇组成的晶体。

USPTO Abstract

本发明的目的是提供提高卢立康唑的溶解度的方法。本发明公开了由卢立康唑和具有1至4个碳原子的短链醇组成的晶体。

Drugs covered by this patent

Patent Metadata

Patent number
CN104284662A
Jurisdiction
CN
Classification
—
Expires
2015-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Pola Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.